Ibogaine Research 2024–2026 — Latest Studies & Trials

2023 Nature Medicine Study

The landmark Stanford study of 30 Special Operations veterans showed 88% PTSD reduction, 78% disability reduction, and significant cognitive improvement — the most compelling ibogaine data published to date.

Texas $50M Clinical Trials

UTHealth Houston and UTMB Health are conducting FDA-approved trials for opioid use disorder and PTSD — the largest government-funded ibogaine research program in history. Results expected 2026–2028.

Trump Executive Order (2026)

President Trump signed an Executive Order in 2026 directing the Department of Veterans Affairs to study ibogaine as a treatment for veteran PTSD — a historic federal acknowledgment of ibogaine's potential.

Growing Publication Pipeline

Peer-reviewed ibogaine publications have increased dramatically since 2020. Multiple Phase 2 trials are underway globally, with Phase 3 trials expected to begin in 2025–2026.

The Research Landscape in 2025–2026

The ibogaine research landscape has transformed since the 2023 Nature Medicine study. That study — showing extraordinary results in Special Operations veterans — served as a catalyst for increased funding, political support, and scientific interest. The Texas Legislature's $50M appropriation, signed into law by Governor Abbott, funds the most ambitious ibogaine research program in US history.

UTHealth Houston and UTMB Health are leading the Texas trials, which focus on opioid use disorder and PTSD. The trials are FDA-approved and follow rigorous clinical protocols, including cardiac monitoring, standardized dosing, and structured integration support. Results are expected to be published in peer-reviewed journals beginning in 2026–2027.

Key Studies and Findings

Mash et al. (2018): Prospective study of 191 opioid-dependent patients treated with ibogaine in a clinical setting. Found significant reductions in withdrawal severity and craving at 1-month follow-up, with 50% reporting abstinence at 3 months.

Noller et al. (2018): New Zealand study of ibogaine for opioid dependence. Found significant reductions in opioid use at 12-month follow-up, with 80% of participants reporting reduced use and 30% reporting complete abstinence.

Ona et al. (2023): Nature Medicine study of ibogaine for PTSD and TBI in Special Operations veterans. Found 88% reduction in PTSD symptoms, 78% reduction in disability, and significant cognitive improvements at 1-month follow-up.

Texas Trials (2024–2028): Ongoing FDA-approved trials at UTHealth Houston and UTMB Health. Primary endpoints include opioid abstinence rates at 6 months and PTSD symptom severity at 3 months. Results expected 2026–2028.

When will ibogaine be FDA approved?

Most experts estimate 5–10 years for potential FDA approval, assuming the Texas trials and other ongoing studies demonstrate safety and efficacy. The FDA's Breakthrough Therapy designation process could accelerate this timeline if ibogaine receives that designation.

What does Trump's Executive Order mean for ibogaine?

The 2026 Executive Order directs the VA to study ibogaine as a treatment for veteran PTSD. This is a significant federal acknowledgment of ibogaine's potential and could lead to VA-funded research, which would accelerate the path to approval.

Where can I read the ibogaine research?

Key ibogaine studies are published in journals including Nature Medicine, the Journal of Psychoactive Drugs, the American Journal of Drug and Alcohol Abuse, and Frontiers in Pharmacology. PubMed is the best resource for finding peer-reviewed ibogaine literature.

How does the Texas research affect practitioners?

Successful Texas trials would dramatically accelerate ibogaine's path to FDA approval and US legalization. Practitioners who are certified now will be positioned to enter the US market when it opens — potentially within 5–10 years.